Pd-l1 expressing hematopoietic stem cells and uses

Abstract

Embodiments disclosed here provide engineered modified hematopoietic stem cells (HSCs), artificially prostaglandin E2 (PGE 2 )-stimulated HSCs, compositions comprising these HSCs, methods of using these modified HSCs for treating autoimmune diseases and disorders and for suppressing the immune system. In particular, the engineered modified HSCs or PGE 2 -stimulated HSCs express the surface marker, programmed cell death-1 ligand 1 (PD-L1).

1 - 55 . (canceled) 
     
     
         56 . A pharmaceutical composition comprising a population of modified, PD-L1+ expressing hematopoietic stem cells (HSCs), produced by an ex vivo method comprising:
 a) contacting a sample of HSCs with a vector carrying an exogenous copy of a nucleic acid encoding a PD-L1 to modify the HSCs whereby the exogenous copy of a nucleic acid is introduced into the HSCs;   b) ex vivo culturing the resultant modified cells from the contacting; and   c) establishing the expression of PD-L1 on the modified HSCs, thereby producing the population of modified HSCs cells expressing PD-L1.   
     
     
         57 . The pharmaceutical composition of  claim 56 , wherein the ex vivo method further comprises establishing that there is at least one-fold increase in the number of PD-L1+ expressing cells compared to non-modified cells. 
     
     
         58 . The pharmaceutical composition of  claim 56 , wherein the sample of HSC is obtained from the bone marrow, umbilical cord, amniotic fluid, chorionic villi, cord blood, placental blood or peripheral blood. 
     
     
         59 . The pharmaceutical composition of  claim 56 , wherein the sample of HSC is obtained from mobilized peripheral blood. 
     
     
         60 . The pharmaceutical composition of  claim 56 , wherein the sample of HSCs is obtained from a healthy individual. 
     
     
         61 . The pharmaceutical composition of  claim 56 , wherein the sample of HSCs is obtained from an individual with a diagnosed disease or disorder. 
     
     
         62 . The pharmaceutical composition of  claim 56 , wherein the diagnosed disease or disorder is an autoimmune disease or disorder. 
     
     
         63 . The pharmaceutical composition of  claim 56 , wherein the autoimmune disease or disorder is Type 1 diabetes (T1D). 
     
     
         64 . The pharmaceutical composition of  claim 56 , wherein the vector is viral vector. 
     
     
         65 . The pharmaceutical composition of  claim 64 , wherein the viral vector is a lentiviral vector. 
     
     
         66 . The pharmaceutical composition of  claim 56 , wherein the nucleic acid is a complementary DNA (cDNA). 
     
     
         67 . The pharmaceutical composition of  claim 56 , wherein the nucleic acid is a genomic DNA. 
     
     
         68 . The pharmaceutical composition of  claim 56 , wherein the nucleic acid is integrated into the genome of the modified cells.